Hepatitis C, illicit drug use and public health: Does Canada really have a viable plan?

Canadian Journal of Public Health

Volumn 97, Issue 6, 2006, Pages 485-488

  Fischer, Benedikt ^a,b,c   Kalousek, Kate ^a,c   Rehm, Jürgen ^a,b   Powis, Jeff ^a,d   Krajden, Mel ^e,f   Reimer, Jens ^g  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Canada; Hepatitis C; Policy; Public health; Street drugs

Indexed keywords

ANTIVIRUS AGENT; ILLICIT DRUG; METHADONE; PEGINTERFERON; RIBAVIRIN;

ARTICLE; CANADA; DRUG DEPENDENCE TREATMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION RISK; INTRAVENOUS DRUG ABUSE; METHADONE TREATMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VIRUS TRANSMISSION;

EID: 33748604198     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03405233     Document Type: Article

References (46)

1. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: Considerations for a targeted treatment approach-The case study of Canada. J Urban Health 2004;81:428-47.
2. Buxton J. Vancouver Drug Use Epidemiology. 1-50. 2003. Vancouver, Canadian Community Epidemiology Network on Drug Use.
3. Fischer B, Rehm J, Brissette S, Brochu S, Bruneau. J, el-Guebaly N, et al. Illicit opioid users in Canada: Comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005;82:250-66.
4. Roy E, Alary M, Morissette C. Épidémiologie de l'hépatite C chez les participants au réseau SurvUDI. 1-16. 2004. Montræal, SurvUDI.
5. Zou S, Forrester L, Giulivi A. Hepatitis C update. Can J Public Health 2003;94(2):127-29.
6. Remis R. A study to characterize the epidemiology of hepatitis C infection in Canada, 2002. Final report. 2004. Ottawa, Health Canada.
7. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: Implications for treatment. Clin Infect Dis 2005;40(Suppl 5):S263-S269.
8. Krahn M, Wong J, Heathcote J, Scully L, Seeff L. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Medical Decision Making 2004;24:20-29.
9. El Saadany S, Coyle D, Giulivi A, Aftal M. Economic burden of hepatitis C in Canada and the potential impact of prevention: Results from a disease model. Eur J Health Econ 2005;6:159-65.
10. Health Canada. Hepatitis C as a roadmap for integrated communicable disease prevention and control: A strategy for the renewal of the Health Canada/Canadian Institutes of Health Research (CIHR) research initiative on hepatitis C. 20-1-2005. Ottawa, Joint Advisory Committee Health Canada/CIHR Research Initiative on Hepatitis C.
11. Reimer J, Schulte B, Castells X, Schafer I, Polywka S, Hedrich D, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: Status quo in the European Union countries. Clin Infect Dis 2005;40(Suppl 5):S373-S378.
12. Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: A comparison of Canadian and Western European jurisdictions over time. CMAJ 2000;162:1709-13.
13. Wood E, Kerr T, Montaner JS, Strathdee SA, Wodak A, Hankins CA, et al. Rationale for evaluating North America's first medically supervised safer-injecting facility. The Lancet Infect Dis 2004;4:301-6.
14. Backmund M, Reimer J, Meyer K, Gerlach JT, Reinhart Z. Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment. Clin Infect Dis 2005;40(Suppl 5):S330-S335.
15. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005;40(Suppl 5):S321-S324.
16. Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40(Suppl 5):S276-S285.
17. Pollack H, Heimer R. The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C. In: Jager J, Limburg W, Kretzschmar M, et al. (Eds.), EMCDDA Monographs: Hepatitis C and Injecting Drug Use: Impact, Costs and Policy Options. Luxembourg: EMCDDA, 2004;345-67.
18. Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Medical Decision Making 2001;21:357-67.
19. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins SG, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999;149:203-13.
20. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-61.
21. Fischer B, Rehm J, Kim G, Robins A. Safer injection facilities (SIFs) for injection drug users (IDUs) in Canada: A review and call for an evidence-focused pilot trial. Can J Public Health 2002;93(5):336-38.
22. Mattick R, Kimber J, Kaldor J, MacDonald M, Weatherburn D, Lapsley H. Final Report of the Evaluation of the Sydney Medically Supervised Injecting Centre. 2003. Sydney, MSIC Evaluation Committee.
23. Kerr T, Tyndall M, Li K, Montaner JSG, Wood E. Safer injection facility use and syringe sharing in injection drug users. The Lancet 2005; early online publication, March 18, 2005.
24. Haydon E, Fischer B. Crack use as a public health problem in Canada: Call for an evaluation of 'safer crack use kits'. Can J Public Health 2005;96(3):185-88.
25. Tortu S, McMahon J, Pouget E, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004;39:211-24.
26. Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, et al. Heroin-assisted treatment as a response to the public health problem of opiate dependence. Eur J Public Health 2002;12:228-34.
27. Thiede H, Hagan H, Murrill C. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health 2000;77:331-45.
28. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Austr N Z J Public Health 2004;28:576-78.
29. Fischer B, Rehm J, Kim G, Kirst M. Eyes wide shut? A conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005;11:1-12.
30. Andonov A, Lin L, Wong G, Hill W, Boulos D, Tweed A, et al. Identification of Newly Acquired Hepatitis C Virus (HCV) Infection in British Columbia Based on Recent Seroconversion; Genotype Distribution for Years 2000-2003. 2nd Canadian Conference on Hepatitis C, Vancouver, Canada. 2004.
31. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
32. Novick DM. The impact of hepatitis C virus infection on methadone maintenance treatment. The Mount Sinai J Med 2000;67:437-43.
33. Strathdee SA, Latka M, Campbell J, O'Driscoll PT, Golub ET, Kapadia F, et al. Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005;40(Suppl 5):S304-S312.
34. Fischer B, Vasdev S, Haydon E, Rehm J, Baliunas D. Willingness for HCV treatment in a sample of Injecting Drug Users (IDUs) in Toronto, Canada. La Presse Médicale 2005;34:1207-10.
35. I-Track: Enhanced Surveillance of Risk Behaviours among Injecting Drug Users in Canada (Pilot Survey Report). 2004. Ottawa, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Population and Public Health Branch, Health Canada.
36. Bell J, Dru A, Fischer B, Levit S, Sarfraz MA. Substitution therapy for heroin addiction. Subst Use Misuse 2002;37:1149-78.
37. Kirahara MM, Van Rompaey SE, Dillingham PW, Koepsell T, Deyo R, Dodge W, et al. Primary care delivery is associated with greater physician experience and improved survival among persons with AIDS. J Gen Intern Med 2003;18:95-103.
38. Backmund M, Meyer K, Edlin B. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004;39:1540-43.
39. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005;40(Suppl 5):S336-S338.
40. EMCDDA European Monitoring Centre for Drugs and Drug Addiction. Annual Report: State of the Drugs Problem in the European Union and Norway. 2004. Lisbon, EMCDDA.
41. Dolan K, Clement N, Rouen D, Rees V, Shearer J, Wodak A. Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? Drug and Alcohol Rev 2004;23:281-86.
42. Hunt N, Griffiths P, Southwell M, Stillwell G, Strang J. Preventing and curtailing injecting drug use: A review of opportunities for developing and delivering 'route transition interventions'. Drug and Alcohol Rev 1999;18:441-51.
43. Gonzalez G, Oliveto A, Kosten T. Combating opiate dependence: A comparison among the available pharmacological options. Expert Opinion on Pharmacotherapy 2004;5:713-25.
44. Mehra S, Cox A, Hoover D, Wang YH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
45. Hoofnagle J. Therapy for acute hepatitis C. N Engl J Med 2001; 345:1495-97.
46. Thimme R, Oldach D, Chang K, Steiger C, Ray S, Chisari F. Determinants of vital clearance and persistence during acute hepatitis C virus infection. J Experimental Med 2001;194:1395-406.